×




Claritas Genomics, Portuguese Version Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Claritas Genomics, Portuguese Version case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Claritas Genomics, Portuguese Version case study is a Harvard Business School (HBR) case study written by Robert F. Higgins, Matthew Preble. The Claritas Genomics, Portuguese Version (referred as “Claritas Genomics” from here on) case study provides evaluation & decision scenario in field of Innovation & Entrepreneurship. It also touches upon business topics such as - Value proposition, Disruptive innovation, Entrepreneurship, Health, Internet, IT, Operations management, Strategy.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Claritas Genomics, Portuguese Version Case Study


Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new tests that provided clearer and more relevant information for physicians to use in treating patients. Claritas wanted to increase the speed at which genomic research discoveries occurred and translate this research into better diagnostic tests. To achieve this, it planned to collaborate with other children's hospitals through a research network it was developing. BCH was the company's majority owner, and Life Technologies (Life), a major manufacturer of sequencing equipment and services, was a minority owner. By the end of the year the CEO of Claritas Genomics, Dr. Patrice Milos, had to put Claritas in a position to grow and needed to have in place the software and IT platforms-the databases, search tools, and other programs-that would help the company reach scale.


Case Authors : Robert F. Higgins, Matthew Preble

Topic : Innovation & Entrepreneurship

Related Areas : Disruptive innovation, Entrepreneurship, Health, Internet, IT, Operations management, Strategy




Calculating Net Present Value (NPV) at 6% for Claritas Genomics, Portuguese Version Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10023371) -10023371 - -
Year 1 3461841 -6561530 3461841 0.9434 3265888
Year 2 3975646 -2585884 7437487 0.89 3538311
Year 3 3939161 1353277 11376648 0.8396 3307396
Year 4 3251332 4604609 14627980 0.7921 2575359
TOTAL 14627980 12686954




The Net Present Value at 6% discount rate is 2663583

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Internal Rate of Return
2. Net Present Value
3. Payback Period
4. Profitability Index

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Claritas Genomics have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Claritas Genomics shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of Claritas Genomics, Portuguese Version

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Innovation & Entrepreneurship Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Claritas Genomics often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Claritas Genomics needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10023371) -10023371 - -
Year 1 3461841 -6561530 3461841 0.8696 3010297
Year 2 3975646 -2585884 7437487 0.7561 3006160
Year 3 3939161 1353277 11376648 0.6575 2590062
Year 4 3251332 4604609 14627980 0.5718 1858960
TOTAL 10465478


The Net NPV after 4 years is 442107

(10465478 - 10023371 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10023371) -10023371 - -
Year 1 3461841 -6561530 3461841 0.8333 2884868
Year 2 3975646 -2585884 7437487 0.6944 2760865
Year 3 3939161 1353277 11376648 0.5787 2279607
Year 4 3251332 4604609 14627980 0.4823 1567965
TOTAL 9493305


The Net NPV after 4 years is -530066

At 20% discount rate the NPV is negative (9493305 - 10023371 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Claritas Genomics to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Claritas Genomics has a NPV value higher than Zero then finance managers at Claritas Genomics can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Claritas Genomics, then the stock price of the Claritas Genomics should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Claritas Genomics should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What will be a multi year spillover effect of various taxation regulations.

What can impact the cash flow of the project.

Understanding of risks involved in the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Claritas Genomics, Portuguese Version

References & Further Readings

Robert F. Higgins, Matthew Preble (2018), "Claritas Genomics, Portuguese Version Harvard Business Review Case Study. Published by HBR Publications.


Palram SWOT Analysis / TOWS Matrix

Basic Materials , Fabricated Plastic & Rubber


PartnerRe Ltd Pf Pref SWOT Analysis / TOWS Matrix

Financial , Insurance (Prop. & Casualty)


Nissei ASB Machine SWOT Analysis / TOWS Matrix

Capital Goods , Misc. Capital Goods


Duerr AG SWOT Analysis / TOWS Matrix

Capital Goods , Constr. & Agric. Machinery


Louis Vuitton SWOT Analysis / TOWS Matrix

Consumer Cyclical , Apparel/Accessories


Xinyi Solar SWOT Analysis / TOWS Matrix

Technology , Semiconductors


GW Pharma ADR SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs


Aegon ADR SWOT Analysis / TOWS Matrix

Financial , Insurance (Life)